Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
156 results about "Chemical Moiety" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A single entity that can be represented as a set of atoms usually connected through a continuous set of covalent bonds.
Method of making functionalized nanotubes
InactiveUS6203814B1Good dispersionImprove adhesionMaterial nanotechnologyCarbon compoundsChemical MoietyFiber
Owner:HYPERION CATALYSIS INT
Abuse-resistant amphetamine compounds
InactiveUS7105486B2Reduced activityRelease is diminished and eliminatedOrganic active ingredientsPeptide/protein ingredientsChemical MoietyDisease
The invention describes compounds, compositions and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
Owner:TAKEDA PHARMA CO LTD
Diazonium salt modification of silk polymer
ActiveUS20090232963A1Change physical propertiesPeptide/protein ingredientsPharmaceutical containersChemical MoietyPolymer science
A method for modifying silk polymer by coupling a chemical moiety to a tyrosine residue of a silk polymer is described herein for the purpose of altering the physical properties of the silk protein. Thus, silk proteins with desired physical properties can be produced by the methods described herein. These methods are particularly useful when the introduction of cells to a mammal is desired, since modifications to the silk protein affect the physical properties and thus the adhesion, metabolic activity and cell morphology of the desired cells. The silk protein can be modified to produce, or modify, a structure that provides an optimal environment for the desired cells.
Owner:TRUSTEES OF TUFTS COLLEGE TUFTS UNIV
Polymeric conjugates for tissue activated drug delivery
InactiveUS20040228831A1Simple methodAbsorption bioactivityPeptide/protein ingredientsPharmaceutical non-active ingredientsChemical MoietyActive agent
The present invention relates to a polymeric drug conjugate with one or more biologically active agents conjugated via an enzymatically cleavable linker to either a regular repeating linear unit comprising a water soluble polymer segment and a multifunctional chemical moiety, or a branched polymer comprising two or more water soluble polymer segments each bound to a common multifunctional chemical moiety, as well as to methods of making such conjugates. The present invention is also directed to pharmaceutical compositions comprising such conjugates and to the use of such conjugates to treat pathological conditions.
Owner:VECSTREETCARED
Abuse-resistant amphetamine compounds
InactiveUS20050054561A1Prevents euphoriaLower potentialBiocidePeptide/protein ingredientsChemical MoietyDisease
The invention describes compounds, compositions and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
Owner:TAKEDA PHARMA CO LTD
Co-localization affinity assays
The invention provides a new assay format for high throughput molecular binding studies at a single molecule level. The invention enables creation of binding event identifiers in a highly parallel way. Individual binding events occur between two agents of a binding pair, e.g., a protein-based binding pair or a binding pair comprising a protein and a chemical moiety. The binding event identifier created through the binding of the two binding agents is unique to that pair, and identification of the binding event identifier is indicative of the binding of these specific may be assessed through a readout that is digital in nature. The invention enables very large sets of thousands or more of different binding agents or potential binding agents to be assayed simultaneously, resolving millions or more of potential interactions, and distinguishing specific interactions from those that are less specific.
Owner:PROGNOSYS BIOSCI
Engineering absorption of therapeutic compounds via colonic transporters
Methods of modifying therapeutic compounds such as drugs to be substrates for active transporters expressed in epithelial cells lining the lumen of the human colon are disclosed. The transporters expressed in the human colon include the sodium dependent multi-vitamin transporter (SMVT), and monocarboxylate transporters 1 and 4 (MCT 1 and MCT 4). The modified compounds can themselves be pharmacologically active, or upon cleavage of a chemical moiety after uptake from the colon, can be metabolized to form a compound that is pharmacologically active (e.g., a prodrug). The modified compounds disclosed herein are suitable for use in extended release oral dosage forms, particularly those that release drug over periods of greater than about 2-4 hours following administration.
Owner:XENOPORT
Microarray based affinity purification and analysis device coupled with solid state nanopore electrodes
InactiveUS20050227239A1Bioreactor/fermenter combinationsBiological substance pretreatmentsChemical MoietyAnalytical chemistry
An apparatus and method for separating and identifying chemical moieties. The apparatus employs a microarray device coupled to a nanopore system. The apparatus both separates and identifies target molecules without the requirement of extraneous tags or fluorescent markers. Methods for using the apparatus are also disclosed.
Owner:AGILENT TECH INC
Abuse-resistant amphetamine prodrugs
The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
Owner:TAKEDA PHARMA CO LTD
Fluorescent polymer superquenching-based bioassays
InactiveUS7122383B2Material nanotechnologyMaterial analysis by observing effect on chemical indicatorChemical MoietyBiologic Assays
A chemical composition including a fluorescent polymer and a receptor that is specific for both a target biological agent and a chemical moiety including (a) a recognition element, (b) a tethering element, and (c) a property-altering element is disclosed. Both the fluorescent polymer and the receptor are co-located on a support. When the chemical moiety is bound to the receptor, the property-altering element is sufficiently close to the fluorescent polymer to alter the fluorescence emitted by the polymer. When an analyte sample is introduced, the target biological agent, if present, binds to the receptor, thereby displacing the chemical moiety from the receptor, resulting in an increase of detected fluorescence. Assays for detecting the presence of a target biological agent are also disclosed.
Owner:QTL BIOSYSTEMS LLC
Modified human interferon-beta polypeptides
InactiveUS7632492B2Altered propertyGood curative effectPeptide/protein ingredientsAntibody mimetics/scaffoldsChemical MoietyBiochemistry
Owner:ALLOZYNE
Hybrid phosphoinositide phospholipids: compositions and uses
InactiveUS20050148042A1Facilitate recruitment of PtdlnsPPeptide/protein ingredientsMicrobiological testing/measurementLipid formationChemical Moiety
The methods and compositions disclosed herein concern the synthesis of a novel class of “two-headed” phospholipid-phosphoinositide hybrids possessing a carbon backbone, such as 2,3-diacylthreitol, erythritol or a synthetic module. The second phospholipid head group allows introduction of a biochemical or chemical moiety in a position orthogonal in space to those occupied by the phosphoinositide head group and the two acyl chains. The diacyl moieties allow for the incorporation of Pea-PIP2 into a lipid bilayer, while the Ptdlns(4,5)P2 moiety in the aqueous layer is specifically recognized by lipid binding proteins. In alternative embodiments of the invention, reporters, for example biotin, fluorophores and / or spin labels, are attached to the free amino group of the head groups of such molecules to specifically target the reporters to the lipid-water interface.
Owner:PRESTWICH GLENN +5
Particle based electrochemiluminescent assays
InactiveUS6881536B1Improve performanceFaster assay timeRuthenium organic compoundsSugar derivativesChemical MoietyAnalyte
A method for the detection of an analyte of interest in a sample, which method comprises the steps of:(1) forming a composition comprising(a) a sample,(b) at least one substance selected from the group consisting of(i) added analyte of interest or an analog of the analyte of interest,(ii) a binding partner of the analyte of interest or its said analog, and(iii) a reactive component capable of binding with (i) or (ii),wherein one of said substances is linked to a label compound having a chemical moiety capable of being induced to luminesce, and(c) a plurality of particles capable of specifically binding with the analyte and / or a substance defined in (b) (i), (b) (ii), or (b) (iii);(2) inducing the label compound to luminesce; and(3) measuring luminescence emitted by the composition to determine the presence of the analyte of interest in the sample.
Owner:BIOVERIS CORP
Bioanalytical instrumentation using a light source subsystem
ActiveUS20070281322A1Low heat generationStrong specificityBioreactor/fermenter combinationsRadiation pyrometryChemical MoietyFluorescence
The invention relates to a light source for irradiating molecules present in a detection volume with one or more selected wavelengths of light and directing the fluorescence, absorbance, transmittance, scattering onto one or more detectors. Molecular interactions with the light allow for the identification and quantitation of participating chemical moieties in reactions utilizing physical or chemical tags, most typically fluorescent and chromophore labels. The invention can also use the light source to separately and simultaneously irradiate a plurality of capillaries or other flow confining structures with one or more selected wavelengths of light and separately and simultaneously detect fluorescence produced within the capillaries or other flow confining structures. In various embodiments, the flow confining structures can allow separation or transportation of molecules and include capillary, micro bore and milli bore flow systems. The capillaries are used to separate molecules that are chemically tagged with appropriate fluorescent or chromophore groups.
Owner:LUMENCOR
Method and composition for chemical synthesis using high boiling point organic solvents to control evaporation
InactiveUS6177558B1Reduce evaporationHigh reaction yieldMaterial nanotechnologySequential/parallel process reactionsChemical synthesisChemical Moiety
A method for reducing evaporation of a liquid reagent solution during solid phase, micro-scale chemical synthesis of a molecule comprising sub-units on an open environment solid support surface. The method includes the steps of providing an open solid support surface including at least one binding site which is functionalized with a reactive chemical moiety; and depositing a substantially controlled and minute volume of liquid reagent solution onto the support surface, and in contact with the binding site. The reagent solution includes reactants contained in at least one relatively high boiling point solvent, in contrast to standard organic solvents for such reagents. Application of a high boiling point solvent substantially reduces evaporation of the reagent solution in the open environment during synthesis on the solid support while enabling the maintenance of a substantially high reaction yield.
Owner:METRIGEN
Holders for arrays
InactiveUS7125523B2Sampled-variable control systemsChemiluminescene/bioluminescenceChemical MoietyArray data structure
A holder for an array unit having a planar substrate and an array of chemical moieties on a surface of the substrate. The holder may include a body with a retaining mechanism which releasably retains an array unit in a seated position. A holder identifier may include data on a characteristic of the holder or seated array or be linkable to a file containing such information. An apparatus, method, and computer program product which may be used with such a holder are also provided.
Owner:AGILENT TECH INC
Multi-triggered self-immolative dendritic compounds
Novel self-immolative dendritic compounds which have a plurality of cleavable trigger units and hence can release a chemical moiety at their focal point upon a multi-triggering mechanism are disclosed. The novel self-immolative dendritic compounds are gated by a molecular logic gate, being either an AND or OR logic gate and hence can be beneficially used in a variety of biological, chemical and physical applications. Processes of preparing, compositions containing and methods utilizing the novel dendritic compounds are further disclosed.
Owner:RAMOT AT TEL AVIV UNIV LTD
Pharmaceutical compositions for prevention of overdose or abuse
The invention relates to pharmaceutical compositions comprised of a chemical moiety attached to an active agent in a manner that substantially decreases the potential of the active agent to cause overdose or to be abused. When delivered at the proper dosage the pharmaceutical composition provides therapeutic activity similar to that of the parent active agent.
Owner:SHIRE PLC
Variants of C-type natriuretic peptides
InactiveUS8377884B2Improve the immunityReduce functionPeptide/protein ingredientsPeptide sourcesChemical MoietyDisease
The present invention provides variants of C-type natriuretic peptide (CNP) comprising one or more deletions; additions of and / or substitutions with natural amino acids, unnatural amino acids and / or peptidomimetics (including peptide bond isosteres); amino acid extensions; and / or other chemical moieties such as, e.g., poly(ethylene glycol) and hydrophobic acids. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders such as, e.g., skeletal dysplasias and achondroplasia, and vascular smooth muscle disorders such as, e.g., restenosis and arteriosclerosis.
Owner:BIOMARIN PHARMA INC
Nanotubes and methods of dispersing and separating nanotubes
Owner:SABIC INNOVATIVE PLASTICS IP BV
Diagnostic method for atherosclerosis
InactiveUS20050244336A1Enough timeUltrasonic/sonic/infrasonic diagnosticsIn-vivo radioactive preparationsChemical MoietySufficient time
The invention relates to a method of identifying / monitoring active atherosclerotic plaques associated with blood vessel walls wherein the plaques comprise activated macrophages having accessible binding sites for a ligand. The method comprises the steps of administering to a patient being evaluated for atherosclerosis an effective amount of a composition comprising a conjugate of a ligand and a chromophore capable of emitting light under predetermined conditions, allowing sufficient time for the ligand conjugate to bind to the activated macrophages, subjecting the blood vessels to the predetermined conditions using a catheter-based device, and identifying active plaques by detecting light emitted by the chromophore using a catheter-based device or by using an external imaging technique. The invention also relates to a similar method wherein a chemical moiety capable of emitting radiation is conjugated to the ligand.
Owner:PURDUE RES FOUND INC
Abuse-resistant amphetamine prodrugs
InactiveUS7659253B2Reducing patient to patient variabilityRisk minimizationBiocideOrganic chemistryDiseaseChemical Moiety
The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
Owner:TAKEDA PHARMA CO LTD
Novel glp-1 derivatives
Novel polypeptide derivatives having protracted profile of action. The present invention relates to a compound which comprises a therapeutic polypeptide linked to an albumin binding residue via a hydrophilic spacer. The present invention also relates to a compound which comprises a therapeutic polypeptide linked to an albumin binding residue via a hydrophilic spacer that separates the polypeptide and the albumin binding residue with a chemical moiety comprising at least 5 non-hydrogen atoms where 30-50% of these atoms are either N or O. In one embodiment of this invention the spacer is defined as -(CH2)lD[(CH2)nE]m(CH2)pQq-, wherein l, m and n independently are 1-20 and p is 0-10, Q is -Z-(CH2)lD[(CH2)nG]m(CH2)p-, q is an integer in the range from 0 to 5, each D, E and G independently are selected from -O-, NR<3>-, -N(COR<4>)-, -PR<5>(O)-, and -P(OR<6>)(O)-, wherein R<3>, R<4>, R<5>, and R<6> independently represent hydrogen or C1-6-alky, Z is selected from -C(O)NH-, -C(O)NHCH2-, -OC(O)NH-, -C(O)NHCH2CH2-, -C(O)CH2-, -C(O)CH=CH-, -(CH2)s-, -C(O)-, -C(O)O- or -NHC(O)-, wherein s is 0 or 1.
Owner:NOVO NORDISK AS
Polymers containing functionalized carbon nanotubes
Owner:HYPERION CATALYSIS INT
Encoded self-assembling chemical libraries (ESACHEL)
InactiveUS20040014090A1Promote formationSugar derivativesNucleotide librariesChemical MoietyNucleotide
The invention concerns a chemical compound comprising a chemical moiety (p) capable of performing a binding interaction with a target molecule (e.g. a biological target) and further comprising an oligonucleotide (b) or functional analogue thereof. In a first embodiment according to the invention, the chemical compound is characterized in that the oligonucleotide (b) or functional analogue comprises at least one self-assembly sequence (b1) capable of performing a combination reaction with at least one self-assembly sequence (b1') of a complentary oligonucleotide or functional analogue bound to another chemical compound comprising a chemical moiety (q). In a second embodiment according to the invention, the chemical compound which comprises a coding sequence (b1) coding for the identification of the chemical moiety (p) is characterized in that the chemical compound further comprises at least one self-assembly moiety (m) capable of performing a combination reaction with at least one self-assembly moiety (m') of a similar chemical compound comprising a chemical moiety (q). The invention comprises corresponding libraries of chemical compounds as well as methods of biopanning of target molecules and of identifying such targets.
Owner:ETH ZZURICH
Amino acid substituted molecules
UndeterminedUS20080096819A1Altered propertyGood curative effectFactor VIIPeptide/protein ingredientsChemical MoietyAmino acid substitution
The invention provides compositions and methods of identifying, modifying and producing modified target molecules, including therapeutic molecules by modification with non-natural amino acids. Certain aspects of the invention include methods of adding a chemical moiety to a target molecule, and the compositions resulting therefrom. Certain aspects of the invention also relate to kits for identifying, modifying and producing modified target molecules described herein.
Owner:ALLOZYNE
Tiling process for constructing a chemical array
InactiveUS6875620B1Low production costSimplify control proceduresBioreactor/fermenter combinationsSequential/parallel process reactionsCompound (substance)Chemical Moiety
A process of constructing an array of chemical moieties having the following steps: forming multiple discrete physical entities (tiles) from a substantially planar material having one or more species of chemical moiety attached thereto; and picking and placing the entities (tiles) stably on a support at spatially distinct ascertainable locations to form an array of chemical moieties. The formed array includes at least two species of chemical moiety and preferably from about 50 to about 1000 species. The claimed invention includes an array formed by this process.
Owner:AGILENT TECH INC
System for delivering therapeutic agents into living cells and cells nuclei
The present invention relates to a novel delivery system for delivering therapeutic agents into living cells, and more particularly, to novel chemical moieties that are designed capable of targeting and / or penetrating cells or other targets of interest and further capable of binding therapeutic agents to be delivered to these cells, and to delivery systems containing same.
Owner:SABAG RFA LTD
Surface acoustic wave sensor
InactiveUS7027921B2More sensitiveAnalysing fluids using sonic/ultrasonic/infrasonic wavesImpedence networksChemical MoietyElectricity
A surface acoustic wave sensor is provided having a piezoelectric material deposited on a piezoelectric substrate. The preferred structure is zinc oxide on ST-cut quartz crystals that allows propagation of a Love mode acoustic wave end is particularly useful in liquid media as well as gas. The sensor can be used to detect biological or chemical moieties.
Owner:MICROTECH CENT MANAGEMENT
Method and composition for chemical synthesis on an open environment support surface using high boiling point organic solvents to control evaporation
InactiveUS6337393B1Reduce evaporationHigh reaction yieldMaterial nanotechnologySequential/parallel process reactionsChemical synthesisChemical Moiety
A method for reducing evaporation of a liquid reagent solution during solid phase, micro-scale chemical synthesis of a molecule comprising sub-units on an open environment solid support surface. The method includes the steps of providing an open solid support surface including at least one binding site which is functionalized with a reactive chemical moiety; and depositing a substantially controlled and minute volume of liquid reagent solution onto the support surface, and in contact with the binding site. The reagent solution includes reactants contained in at least one relatively high boiling point solvent, in contrast to standard organic solvents for such reagents. Application of a high boiling point solvent substantially reduces evaporation of the reagent solution in the open environment during synthesis on the solid support while enabling the maintenance of a substantially high reaction yield.
Owner:METRIGEN INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com